- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
AbbVie admitted an HCP registration webpage went live in a version that differed from the certified copy after an agency uploaded the…
Two UK-based GSK employees ‘liked’ a LinkedIn post about US FDA approval for Jemperli + chemotherapy. Panel ruled this brought the post…
A health professional alleged AstraZeneca’s Fluenz Tetra post-administration booklet omitted two SmPC safety requirements. Panel found the points were covered pre-administration and…
Unapproved social posts and an NHS Trust web article recruiting for Moderna’s NextCOVE trial were found misleading and unclear about Moderna’s involvement.…
Four UK Pfizer employees ‘liked’ a third‑party LinkedIn post naming talazoparib. Panel said the likes proactively disseminated POM info to the public:…
A third‑party medical publication email drove HCPs to a webpage containing Gilead‑sponsored content, but the email didn’t declare Gilead’s involvement upfront. Breach…
PMCPA found Britannia breached Clauses 11.2 and 5.1 after its nurse service package deal agreement contemplated home initiation (off-label) and a sponsored…
Three national newspaper business articles based on a Novo Holdings interview included positive Wegovy/SELECT trial statements. PMCPA found public advertising and unbalanced…
Following a BMJ analysis of EUCTR reporting, the PMCPA reviewed two Janssen trials shown as unreported. Both were cancelled with no patients…
A GP alleged a £250 honorarium plus hospitality and transport to attend a Movicol advisory forum was excessive and a loophole to…
Wyeth challenged Roche/Chugai media claims about unlicensed tocilizumab. The Panel ruled several claims misleading, unsubstantiated and exaggerated, and one statement disparaging anti‑TNF…
A primary care trust chief pharmacist complained about a Plavix leavepiece and representative conduct. The Panel ruled it was misleading to imply…
Two BMJ advertisements for Gaviscon Advance used in-vitro study abstracts but implied in-vivo/clinical oesophageal protection and wider clinical benefit. The Panel ruled…
A GP challenged a Prescriber journal ad for Micardis and Micardis Plus. The Panel ruled the headline implied unproven long-term cardiovascular benefits,…
A Champix journal ad claimed significantly greater quit success vs an NRT patch. The PMCPA Panel ruled the claim misleading because the…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.